



## THE ICBP NEWSLETTER

Dear Colleague,

Welcome to the first ICBP newsletter of 2018. This year will be a busy one, with the final publications from phase 1 expected in the first half of this year, and the first outputs and publications from phase 2 towards the second half (such as the updated cancer survival benchmark and novel outcome metrics). With all this activity, we will make the newsletter more frequent, ensuring you are up to date with our progress.

This newsletter contains updates on:

- The first ICBP phase 2 researcher workshop
- The ICBP SurvMark-2 team visiting Australia and New Zealand
- ICBP presenting at the Ca-PR1 conference

We hope to bring you many more examples of great collaboration and advocacy from the ICBP network throughout 2018, as well as some novel findings from across phases 1 and 2.

With best wishes,

The ICBP programme management team



### INAUGURAL RESEARCHER WORKSHOP

At the end of February, the ICBP programme management team organised the first ICBP phase 2 researcher workshop. Held in London, it was attended by research teams from all modules, as well as clinicians, academic reference group members and programme board members Heather Bryant (Canada), Gareth Davies (Wales), Bob Thomas (Victoria, Australia), Chris Harrison (England) and Sara Hiom (Cancer Research UK).

We explored the preliminary SurvMark-2 data on oesophageal and gastric cancers, and invited our upper GI clinical lead Piers Gatenby and colleagues to help us dive deeper into this data.

We will be working closely with all our research teams to continue engaging our clinical groups, and ensure that their vital expertise strengthens the interpretation of the partnership's findings.

[Read about phase 2](#)



## ICBP IN AUSTRALIA, NEW ZEALAND AND WALES

A team from the International Agency for Research on Cancer are leading SurvMark-2, the updated international cancer survival benchmark. They have been busy speaking to local cancer registry contacts over the last few months.

At the end of last year, Isabelle Soerjomataram had the opportunity to visit New South Wales and Victoria (Australia) and New Zealand to carry out these key informant interviews. Isabelle visited the Cancer Society of New Zealand's offices and was pictured in the local media with the Society's CEO and ICBP Programme Board member Mike Kernaghan.

In October, Sam Harrison and Irene Reguilon from the programme management team were invited to join ICBP Programme Board member Gareth Davies and the Deputy Chief Medical Officer for Wales to discuss the preliminary findings from ICBP Module 4.

Module 4 is looking to explore and compare the time taken from patients first noticing symptoms to when they start treatment for breast, colorectal, lung and ovarian cancers across ten jurisdictions. The results will be published throughout 2018 and should help jurisdictions to understand where there are opportunities to revise parts of their health system, to improve cancer patient experience and outcomes.

[Read the NZ press story](#)



## ICBP AT CA-PRI CONFERENCE

This year, the annual Cancer and Primary Care Research International Network (Ca-PRI) conference will be held in Groningen, Netherlands, towards the end of April. The ICBP is usually well represented at this conference, with many collaborators attending and showcasing their findings. A poster showcasing the differences in international diagnostic data availability will also be presented.

Sara Hiom, Sam Harrison and Irene Reguilon from the Programme Management team will be attending, and would like to organise an ICBP meet-up over lunch or a coffee break with ICBP colleagues.

[I will be at Ca-PRI](#)

## CONTACT THE TEAM

If you would like to find out more about anything in the newsletter, suggest content for the webpages, or would like to unsubscribe from this newsletter, please get in touch.

[Email the team](#)



You have received this email as a result of a recent donation, registration or specific request.

To stop receiving communications from the International Cancer Benchmarking Partnership (ICBP) please email the programme management team at

[ICBP@cancer.org.uk](mailto:ICBP@cancer.org.uk).

Our supporters are at the heart of everything we achieve at Cancer Research UK.

[Read our Fundraising Promise.](#)

This email is from [Cancer Research UK](#). Cancer Research UK is a registered charity in England and Wales (1089464), Scotland (SC041666) and the Isle of Man (1103). A company limited by guarantee. Registered company in England and Wales (4325234) and the Isle of Man (5713F). Registered address: Angel Building, 407 St John Street, London EC1V 4AD.